Skip to main content

Advertisement

Table 1 Baseline characteristics

From: Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses

Variables Number of patients (N = 183)
No %
Age, median (range) 46 (25–71)  
Histology   
 Invasive ductal carcinoma 167 91.3
Premenopausal/Postmenopausal 109/74 59.6/40.4
Regimen of Neoadjuvant Chemotherapy   
 Concurrent anthracycline + taxane 128 69.9
 Sequential anthracycline + taxane 47 25.7
 HER-2 directed agent containing regimen 10 5.5
 Doxorubicin plus cyclophosphamide 1 0.5
Type of Surgery   
 Breast conserving surgery 104 56.8
 Mastectomy 79 43.2
Initial Clinical Stage   
 IIA 3 1.6
 IIB 27 14.8
 IIIA 94 51.4
 IIIB 26 14.2
 IIIC 33 18.0
Hormone receptor and HER2 expression status   
 Hormone receptor (+) 106 57.9
 HER2 (+) 58 31.7
Pathologic Stage   
 yp0 22 12.0
 ypIA 41 22.4
 ypIIA 42 23.0
 ypIIB 22 12.0
 ypIIIA 38 20.8
 ypIIIB 2 1.1
 ypIIIC 16 8.7
Adjuvant therapy   
 Radiation therapy 158 86.3
 Chemotherapy 62 33.9
 Trastuzumab 55 94.8 % of patients with HER2 positive tumor
 Hormonal therapy 103 97.1 % of patients with HR positive tumor
  1. HER2 human epidermal growth factor receptor 2, TNBC triple negative breast cancer